GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.
GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult Acute Lymphoblastic Leukemia. A Prospective Multicentric GIMEMA Trial.
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
This PHASE2 trial investigates Acute Lymphoblastic Leukemia and is currently ongoing. Gruppo Italiano Malattie EMatologiche dell'Adulto leads this study, which shows 8 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Completed → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Completed PHASE2
First recorded
Oct 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gruppo Italiano Malattie EMatologiche dell'Adulto
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.